子宫内膜增生患者的前哨淋巴结定位:保留还是摒弃的实践
本研究回顾性比较了术前子宫内膜活检为癌前病变、接受子宫切除术时行或不行前哨淋巴结(SLN)切除的患者结局。结果显示SLN评估似乎安全,可检出少量隐匿性淋巴结转移并为辅助治疗提供分期信息;作者建议术前咨询中讨论SLN定位并采用共享决策方式提供。
要点
- SLN切除组与未切除组30天术后不良事件率分别为9%和13%,无显著差异(p=0.9)。
- 最终病理中44%(98/221)为1-2级子宫内膜样癌,其中4例(4%)为IB期或更高。
- 98例癌症患者中10例(10%)接受辅助治疗,均在SLN组。
核心结论
- SLN评估似乎安全,可检出少量隐匿性淋巴结转移并为分期上调者提供额外分期信息以指导辅助治疗。
- 作者建议术前咨询中讨论SLN定位,并采用共享决策方式提供。
研究设计与样本
- 回顾性识别2017年1月1日至2021年12月31日在本机构因术前子宫内膜活检为癌前病变接受子宫切除术伴或不伴SLN定位/切除的患者。
- 共纳入221例患者,其中161例(73%)行SLN切除,60例(27%)未行SLN切除。
主要发现
- 两组中位年龄和体重指数相似。
- SLN定位/切除组中位手术时间130分钟,未行SLN组为136分钟(p=0.6)。
- 30天术后不良事件率分别为9%(15/161)和13%(8/60)(p=0.9)。
- 221例中98例(44%)最终病理为1-2级子宫内膜样癌,其中4例(4%)为IB期或更高。
- 98例中10例(10%)接受辅助治疗,均在SLN组。
临床怎么用
- 作者建议术前咨询中讨论SLN定位,并采用共享决策方式提供。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: To compare outcomes of patients with premalignant endometrial pathology undergoing hysterectomy with or without sentinel lymph node (SLN) removal. Outcomes of interest included surgical adverse events (AEs), cancer status on final pathology, postoperative treatment, and The Cancer Genome Atlas (TCGA) molecular risk profiles. METHODS: We retrospectively identified patients with premalignant pathology on preoperative endometrial biopsy who underwent hysterectomy with or without SLN mapping/excision at our institution from 01/01/2017-12/31/2021. Clinical, pathologic, surgical, and TCGA profiling data were abstracted. Appropriate statistical tests were used. RESULTS: Of 221 patients identified, 161 (73%) underwent hysterectomy with SLN excision and 60 (27%) underwent hysterectomy without SLN excision. Median age and body mass index were similar between groups. Median operative time was 130 min for those who underwent SLN mapping/excision versus 136 min for those who did not (p = 0.6). Thirty-day postoperative AE rates were 9% (n = 15/161) and 13% (n = 8/60), respectively (p = 0.9). Ninety-eight (44%) of 221 patients had grade 1-2 endometrioid endometrial cancer on final pathology (4 [4%] were stage IB or higher). Ten (10%) of 98 patients, all within the SLN group, received adjuvant treatment. Among all patients, of 33 (15%) with TCGA molecular classification data, 27 (82%) had copy number-low, 3 (9%) microsatellite instability-high, 2 (6%) POLE-ultramutated, and 1 (3%) copy number-high disease. CONCLUSIONS: SLN assessment appears safe, detects a small number of occult nodal metastases for those upstaged, and provides additional staging information that can guide adjuvant treatment. SLN mapping should be discussed in preoperative counseling and offered using a shared decision-making approach.
引用
- Mueller JJ, Rios-Doria E, Park KJ, et al. Sentinel lymph node mapping in patients with endometrial hyperplasia: A practice to preserve or abandon? Gynecol Oncol. 2022. PMID: 36334496. doi:10.1016/j.ygyno.2022.10.017
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。